Glaukos Research and Development Expenses 2014-2024 | GKOS

Glaukos research and development expenses for the twelve months ending December 31, 2024 were $0.151B, a 4.79% increase year-over-year.

  • Glaukos annual research and development expenses for 2024 were $0.151B, a 4.79% increase from 2023.
  • Glaukos annual research and development expenses for 2023 were $0.144B, a 7.88% increase from 2022.
  • Glaukos annual research and development expenses for 2022 were $0.133B, a 31.95% increase from 2021.

Glaukos Research and Development Expenses 2014-2024 | GKOS

  • Glaukos annual research and development expenses for 2024 were $0.151B, a 4.79% increase from 2023.
  • Glaukos annual research and development expenses for 2023 were $0.144B, a 7.88% increase from 2022.
  • Glaukos annual research and development expenses for 2022 were $0.133B, a 31.95% increase from 2021.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$216.7B
Thermo Fisher Scientific (TMO)$203.1B
Alcon (ALC)$44.2B
Edwards Lifesciences (EW)$44B
IDEXX Laboratories (IDXX)$36.9B
DexCom (DXCM)$35B
IQVIA Holdings (IQV)$34.6B
Mettler-Toledo (MTD)$27.3B
Waters (WAT)$22.4B
STERIS (STE)$21.8B
SONOVA HOLDING (SONVY)$19.6B
Hologic (HOLX)$14.4B
Fresenius Medical Care AG KGaA (FMS)$13.6B
Penumbra (PEN)$11.7B
Sysmex ADR (SSMXY)$11.5B
Globus Medical (GMED)$11.5B
Masimo (MASI)$9.6B
Teleflex (TFX)$8.1B
Integer Holdings (ITGR)$4.8B
Inari Medical (NARI)$4.7B
PROCEPT BioRobotics (PRCT)$3.5B
Veracyte (VCYT)$3.3B
Nihon Kohden (NHNKY)$2.7B
TransMedics (TMDX)$2.7B
LivaNova (LIVN)$2.6B
Elekta AB (EKTAY)$2.3B
Tandem Diabetes Care (TNDM)$2.1B
Integra LifeSciences Holdings (IART)$1.7B
Alphatec Holdings (ATEC)$1.5B
Pulse Biosciences (PLSE)$1.2B